Table 1.
Patient and Tumor Characteristics
| Characteristics | ||
|---|---|---|
| Median age (range) | 54 (28–80) | Overall number (%) |
| Race | White | 192 (74.7%) |
| Black | 26 (10.1%) | |
| Asian | 7 (2.7%) | |
| Other | 32 (12.5%) | |
| Tumor Stage at Diagnosis | Stage 0–2 | 141 (54.9%) |
| Stage 3 | 67 (26.1%) | |
| Stage 4 | 48 (18.7%) | |
| Tumor Subtype | HR+/HER2− | 165 (64.2%) |
| HR+/HER2+ | 24 (9.3%) | |
| HR−/HER2+ | 8 (3.1%) | |
| TNBC | 60 (23.3) | |
|
Recurrence-Free Survival for Overall Group (for patients who were not Stage IV at diagnosis) | ||
| Median RFS (month) |
pts # with RFS ≤12 months |
|
| HR+ (n=165) | 38.37 | 24 (14.5%) |
| HER2+ (n=32) | 21.33 | 8 (25%) |
| TNBC (n=60) | 12.75 | 23 (38.3%) |
|
Sample Sequenced (total 268 samples from 257 patients) | ||
| Overall number (%) | ||
| Primary 191 (71.3%) | Therapy-naive | 120 (44.7%) |
| Post-neoadjuvant chemotherapy | 67 (25%) | |
| Post-neoadjuvant Endocrine therapy |
4(1.4%) | |
| Local-Regional recurrence | 8 (3.0%) | |
| Distant Metastases | 69 (25.7%) | |
| Soft tissue | 24 (9.0%) | |
| Bone | 8 (3.0%) | |
| Liver | 13 (4.9%) | |
| Lung | 7 (2.6%) | |
| Other | 17 (6.3%) | |
|
Patients with both primary and recurrence/metastasis (n=11) |
Primary and recurrence | 1 (0.4%) |
| Primary and metastasis | 10 (3.9%) | |